{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:08Z","timestamp":1788865988877,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["517063424"],"award-info":[{"award-number":["517063424"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00198-026-08039-w","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T22:25:50Z","timestamp":1777069550000},"page":"1337-1342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment using asfotase alfa for delayed healing of a metatarsal stress fracture in an adolescent girl with hypophosphatasia"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7522-4887","authenticated-orcid":false,"given":"Oskar","family":"Windels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-8983","authenticated-orcid":false,"given":"Alexander","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-7294","authenticated-orcid":false,"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-0983","authenticated-orcid":false,"given":"Timur","family":"Yorgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0200-8431","authenticated-orcid":false,"given":"Florian","family":"Barvencik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"4","key":"8039_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","volume":"98","author":"JL Millan","year":"2016","unstructured":"Millan JL, Whyte MP (2016) Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int 98(4):398\u2013416. https:\/\/doi.org\/10.1007\/s00223-015-0079-1","journal-title":"Calcif Tissue Int"},{"key":"8039_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1749-6632.2010.05387.x","volume":"1192","author":"MP Whyte","year":"2010","unstructured":"Whyte MP (2010) Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci 1192:190\u2013200. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05387.x","journal-title":"Ann N Y Acad Sci"},{"issue":"5065","key":"8039_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/212901a0","volume":"212","author":"H Fleisch","year":"1966","unstructured":"Fleisch H, Russell RGG, Straumann F (1966) Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212(5065):901\u2013903. https:\/\/doi.org\/10.1038\/212901a0","journal-title":"Nature"},{"issue":"10","key":"8039_CR4","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00198-011-1528-y","volume":"22","author":"F Barvencik","year":"2011","unstructured":"Barvencik F, Beil FT, Gebauer M et al (2011) Skeletal mineralization defects in adult hypophosphatasia - a clinical and histological analysis. Osteoporos Int 22(10):2667\u20132675. https:\/\/doi.org\/10.1007\/s00198-011-1528-y","journal-title":"Osteoporos Int"},{"issue":"9","key":"8039_CR5","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00198-017-4087-z","volume":"28","author":"T Schmidt","year":"2017","unstructured":"Schmidt T, Mussawy H, Rolvien T et al (2017) Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Osteoporos Int 28(9):2653\u20132662. https:\/\/doi.org\/10.1007\/s00198-017-4087-z","journal-title":"Osteoporos Int"},{"issue":"8","key":"8039_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10215","volume":"3","author":"T Schmidt","year":"2019","unstructured":"Schmidt T, Rolvien T, Linke C et al (2019) Outcome of teriparatide treatment on fracture healing complications and symptomatic bone marrow edema in four adult patients with hypophosphatasia. JBMR Plus 3(8):e10215. https:\/\/doi.org\/10.1002\/jbm4.10215","journal-title":"JBMR Plus"},{"issue":"6","key":"8039_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4158\/EP.12.6.676","volume":"12","author":"HM Khandwala","year":"2006","unstructured":"Khandwala HM, Mumm S, Whyte MP (2006) Low serum alkaline phosphatase activity and pathologic fracture: case report and brief review of hypophosphatasia diagnosed in adulthood. Endocr Pract 12(6):676\u2013681. https:\/\/doi.org\/10.4158\/EP.12.6.676","journal-title":"Endocr Pract"},{"issue":"4","key":"8039_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP (2016) Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12(4):233\u2013246. https:\/\/doi.org\/10.1038\/nrendo.2016.14","journal-title":"Nat Rev Endocrinol"},{"key":"8039_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bone.2019.05.036","volume":"127","author":"T Rolvien","year":"2019","unstructured":"Rolvien T, Schmidt T, Schmidt FN et al (2019) Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia. Bone 127:67\u201374. https:\/\/doi.org\/10.1016\/j.bone.2019.05.036","journal-title":"Bone"},{"key":"8039_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115794","volume":"143","author":"J Sturznickel","year":"2021","unstructured":"Sturznickel J, Schmidt FN, von Vopelius E et al (2021) Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia. Bone 143:115794. https:\/\/doi.org\/10.1016\/j.bone.2020.115794","journal-title":"Bone"},{"issue":"8","key":"8039_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4158\/EP15890.OR","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Mazhari AM, Wilczynski C, Kadanoff R, Mumm S, Whyte MP (2016) Adult hypophosphatasia treated with teriparatide: report of 2 patients and review of the literature. Endocr Pract 22(8):941\u2013950. https:\/\/doi.org\/10.4158\/EP15890.OR","journal-title":"Endocr Pract"},{"issue":"10","key":"8039_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, SalmanGreenberg NJCF, BoberSalman MBNF et al (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366(10):904\u2013913. https:\/\/doi.org\/10.1056\/NEJMoa1106173","journal-title":"N Engl J Med"},{"issue":"5","key":"8039_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jbm4.10052","volume":"2","author":"P Klidaras","year":"2018","unstructured":"Klidaras P, Severt J, Aggers D, Payne J, Miller PD, Ing SW (2018) Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy. JBMR Plus 2(5):304\u2013307. https:\/\/doi.org\/10.1002\/jbm4.10052","journal-title":"JBMR Plus"},{"issue":"2","key":"8039_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Simmons JH, Moseley S et al (2019) Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol 7(2):93\u2013105. https:\/\/doi.org\/10.1016\/S2213-8587(18)30307-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8039_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117033","volume":"181","author":"MP Whyte","year":"2024","unstructured":"Whyte MP, Zhang F, Mack KE et al (2024) Pyridoxine challenge reflects pediatric hypophosphatasia severity and thereby examines tissue-nonspecific alkaline phosphatase\u2019s role in vitamin B(6) metabolism. Bone 181:117033. https:\/\/doi.org\/10.1016\/j.bone.2024.117033","journal-title":"Bone"},{"issue":"2","key":"8039_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1042\/cs0940203","volume":"94","author":"SJ Iqbal","year":"1998","unstructured":"Iqbal SJ, Brain A, Reynolds TM, Penny M, Holland S (1998) Relationship between serum alkaline phosphatase and pyridoxal-5\u2032-phosphate levels in hypophosphatasia. Clin Sci Lond 94(2):203\u2013206","journal-title":"Clin Sci Lond"},{"issue":"1-2","key":"8039_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ymgme.2018.07.006","volume":"125","author":"T Akiyama","year":"2018","unstructured":"Akiyama T, Kubota T, Ozono K et al (2018) Pyridoxal 5\u2019-phosphate and related metabolites in hypophosphatasia: effects of enzyme replacement therapy. Mol Genet Metab 125(1\u20132):174\u2013180. https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.006","journal-title":"Mol Genet Metab"},{"issue":"9","key":"8039_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00198-019-04921-y","volume":"30","author":"AA Khan","year":"2019","unstructured":"Khan AA, Josse R, Kannu P et al (2019) Hypophosphatasia: Canadian update on diagnosis and management. Osteoporos Int 30(9):1713\u20131722. https:\/\/doi.org\/10.1007\/s00198-019-04921-y","journal-title":"Osteoporos Int"},{"issue":"1","key":"8039_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-019-2420-8","volume":"20","author":"W H\u00f6gler","year":"2019","unstructured":"H\u00f6gler W, Langman C, Gomes da Silva H et al (2019) Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord 20(1):80. https:\/\/doi.org\/10.1186\/s12891-019-2420-8","journal-title":"BMC Musculoskelet Disord"},{"key":"8039_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-025-00906-5","volume":"23","author":"KM Dahir","year":"2025","unstructured":"Dahir KM, Dunbar NS (2025) Medical management of hypophosphatasia: review of data on asfotase alfa. Curr Osteoporos Rep 23:14. https:\/\/doi.org\/10.1007\/s11914-025-00906-5","journal-title":"Curr Osteoporos Rep"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08039-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08039-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08039-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:54Z","timestamp":1788865434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08039-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["8039"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08039-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been performed in accordance with the 1964 Declaration of Helsinki and its later amendments, and approval for this project was obtained from the local ethics committee (Ethikkomission der \u00c4rztekammer Hamburg, PV5364).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient.","order":2,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AS and TY state that they have no conflict of interest. NM has received travel support, consulting fees and\/or honoraria from Amicus, BioMarin Pharmaceutical, Chiesi, GC Biopharma, JCR Pharmaceuticals, Sanofi Genzyme, Takeda, Ultragenyx, and Regenxbio. OW has received a travel grant from Inozyme, FB has received honoraria, served as a speaker, and acted as a consultant for Alexion, Diasorin, Blueprint Medicines (Germany) GmbH, UCB, and FOMF GmbH Forum f\u00fcr medizinische Fortbildung, and has received institutional research grants from Alexion and UCB.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}